Non-Crossing Deep Quantile Regression for Distributional Survival Prediction
Organizations: Department of Biostatistics, University of North Carolina at Chapel Hill · Servier Pharmaceuticals, Boston, MA · The Hong Kong Polytechnic University, Hung Hom, Hong Kong, China · Astellas Pharma US, Northbrook, IL
Abstract
In survival analysis the way covariates act on the risk of an event often differs between early and late failure times, yet hazard- and mean-based summaries collapse this variation into a single number. Quantile-based modeling instead describes the full conditional distribution on the original time scale, but existing censored-data methods are either inflexible or produce logically inconsistent crossing quantile curves. We propose a Censored Non-crossing Quantile (CNQ) framework for right-censored data that jointly estimates several conditional survival quantiles and guarantees valid ordering by construction, with flexibility supplied by Kolmogorov-Arnold and Transformer backbones, and we establish a finite-sample excess-risk bound holding jointly across all fitted quantile levels. Across 27 simulation settings and six cohorts the framework attains lower pinball loss than quantile-, hazard- and tree-based competitors whenever the conditional distribution is asymmetric, with interval coverage closer to nominal on all six. In two clinical case studies (METABRIC, breast cancer; FLCHAIN, population mortality) it recovers covariate effects that vary across the survival distribution and would be hidden by a single hazard ratio, and yields coherent individualized quantile milestones. Code: https://github.com/BIG-S2/deepcnq
Figures & tables
| Data set | Size | Covariates | Censored% |
|---|---|---|---|
| SUPPORT | 8,873 | 14 | 32 |
| METABRIC | 1,904 | 9 | 42 |
| GBSG | 2,232 | 7 | 43 |
| GBSG-500 | 500 | 7 | 42 |
| NKI70 | 144 | 8 | 67 |
| FLCHAIN | 7,874 | 7 | 72 |
| MACE | |||||||
|---|---|---|---|---|---|---|---|
| Model | |||||||
| TransKAN-CNQ | 0.215 | 0.226 | 0.223 | 0.079 | 0.109 | 0.090 | |
| Trans-CNQ | 0.224 | 0.230 | 0.223 | 0.092 | 0.102 | 0.091 | |
| KAN-CNQ | 0.227 | 0.231 | 0.231 | 0.089 | 0.098 | 0.099 | |
| GBSG | GBSG-500 | METABRIC | SUPPORT | NKI70 | FLCHAIN | |
| Proposed methods | ||||||
| TransKAN-CNQ | .199 .006 | .206 .015 | .215 .022 | .486 .011 | .251 .066 | .279 .015 |
| Trans-CNQ | .200 .006 | .204 .017 | .224 .024 | .487 .010 | .242 .044 | .282 .015 |
| KAN-CNQ | .203 .007 | .210 .015 | .227 .025 | .490 .010 | .251 .058 | .280 .016 |
| Deep learning baselines | ||||||
| DeepQuantreg | .206 .007 | .220 .018 | .243 .024 | .492 .009 | .305 .100 | .287 .015 |
| GBSG | GBSG-500 | METABRIC | SUPPORT | NKI70 | FLCHAIN | |
| Proposed methods | ||||||
| TransKAN-CNQ | .789 .038 | .802 .085 | .784 .105 | .782 .030 | .690 .297 | .795 .061 |
| Trans-CNQ | .808 .037 | .787 .073 | .720 .160 | .778 .043 | .759 .229 | .806 .055 |
| KAN-CNQ | .784 .039 | .818 .080 | .765 .134 | .783 .024 | .805 .227 | .828 .042 |
| Deep learning baselines | ||||||
| DeepQuantreg | .793 .046 | .788 .057 | .759 .075 | .793 .024 | .625 .233 | .802 .039 |
| Dataset | Censoring | Outcome | Covariates | Domain | |
|---|---|---|---|---|---|
| METABRIC | 1,904 | 42% | Overall survival (months) | 9 | Breast cancer |
| FLCHAIN | 7,874 | 72% | Time to death (days) | 7 | General population |
| Model | |||||
|---|---|---|---|---|---|
| TransKAN-CNQ | 0.168 0.014 | 0.278 0.024 | 0.310 0.031 | 0.215 0.033 | 0.103 0.018 |
| Trans-CNQ | 0.171 0.013 | 0.283 0.022 | 0.321 0.034 | 0.231 0.037 | 0.115 0.026 |
| KAN-CNQ | 0.177 0.013 | 0.290 0.020 | 0.325 0.033 | 0.229 0.043 | 0.114 0.032 |
| Model | |||||
|---|---|---|---|---|---|
| TransKAN-CNQ | 0.278 0.022 | 0.396 0.024 | 0.378 0.020 | 0.237 0.012 | 0.107 0.006 |
| Trans-CNQ | 0.280 0.021 | 0.399 0.023 | 0.382 0.021 | 0.239 0.014 | 0.108 0.006 |
| KAN-CNQ | 0.277 0.021 | 0.396 0.023 | 0.380 0.021 | 0.238 0.013 | 0.107 0.006 |
| Any adjacent | Adjacent pair | |||
|---|---|---|---|---|
| Real data (6 cohorts) | ||||
| Simulation (27 settings) |
| Event | ER | Age | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient A | 28.3 | 48.7 | 91.5 | 138.8 | 184.8 | 41.8 | Yes | ER+ | 86 |
| Patient B | 34.0 | 56.6 | 100.6 | 153.5 | 204.4 | 119.5 | Yes | ER+ | 69 |
| Patient C | 36.9 | 64.7 | 102.7 | 149.9 | 187.8 | 85.6 | Yes | ER+ | 78 |
| Patient D | 29.8 | 56.3 | 119.3 | 211.2 | 297.7 | 104.7 | Yes | ER | 58 |
| Patient E | 34.0 | 56.7 | 99.8 | 147.9 | 192.4 | 100.3 | Yes | ER+ | 74 |
| Model | Tercile | Pinball Loss | 80% Cov. | 50% Cov. |
|---|---|---|---|---|
| TransKAN-CNQ | Narrow | 20.10 | 0.759 | 0.476 |
| Medium | 26.30 | 0.747 | 0.451 | |
| Wide | 29.30 | 0.830 | 0.517 | |
| Trans-CNQ | Narrow | 20.59 | 0.713 | 0.424 |
| Medium | 28.02 | 0.705 | 0.396 | |
| Wide | 30.78 | 0.798 | 0.526 |
| Event | Sex | Age | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient A | 439 | 1,062 | 1,876 | 2,815 | 3,757 | 2,047 | Yes | F | 90 |
| Patient B | 155 | 614 | 1,735 | 2,965 | 4,293 | 2,706 | Yes | M | 59 |
| Patient C | 847 | 2,086 | 3,221 | 4,207 | 5,363 | 2,981 | Yes | F | 50 |
| Patient D | 658 | 1,895 | 3,533 | 5,063 | 6,639 | 3,347 | Yes | F | 70 |
| Patient E | 614 | 1,731 | 3,246 | 4,586 | 5,940 | 3,245 | Yes | M | 69 |
| Model | Tercile | Pinball Loss | 80% Cov. | 50% Cov. | Avg. |
|---|---|---|---|---|---|
| TransKAN-CNQ | Narrow | 354.7 | 0.773 | 0.469 | 234.6 |
| Medium | 389.8 | 0.856 | 0.527 | 105.0 | |
| Wide | 400.8 | 0.884 | 0.582 | 94.2 | |
| Trans-CNQ | Narrow | 359.3 | 0.778 | 0.479 | 224.2 |
| Medium | 393.0 | 0.864 | 0.546 | 106.3 | |
| Wide | 403.7 | 0.891 | 0.614 | 103.3 |
| Cutoff (months) | Latent | Trans-CNQ cens. | Weibull cens. |
|---|---|---|---|
| 24 | |||
| 48 | |||
| 72 | |||
| 96 |
| coverage | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Model | none | 90th | 95th | 99th | none | 90th | 95th | 99th | |
| TransKAN-CNQ | 0.279 | 0.284 | 0.282 | 0.280 | 0.795 | 0.817 | 0.814 | 0.806 | |
| Trans-CNQ | 0.282 | 0.286 | 0.285 | 0.283 | 0.806 | 0.825 | 0.822 | 0.814 | |
| KAN-CNQ | 0.280 | 0.284 | 0.283 | 0.281 | 0.828 | 0.841 | 0.840 | 0.835 | |
| coverage | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Model | none | 90th | 95th | 99th | none | 90th | 95th | 99th | |
| TransKAN-CNQ | 0.215 | 0.222 | 0.221 | 0.218 | 0.784 | 0.822 | 0.820 | 0.803 | |
| Trans-CNQ | 0.224 | 0.225 | 0.223 | 0.225 | 0.720 | 0.797 | 0.795 | 0.763 | |
| KAN-CNQ | 0.227 | 0.231 | 0.230 | 0.230 | 0.765 | 0.810 | 0.808 | 0.792 | |
| coverage | |||||||
|---|---|---|---|---|---|---|---|
| Model | 65/15/20 | 50/25/25 | 80/10/10 | 65/15/20 | 50/25/25 | 80/10/10 | |
| TransKAN-CNQ | 0.228 | 0.226 | 0.242 | 0.736 | 0.738 | 0.670 | |
| Trans-CNQ | 0.229 | 0.224 | 0.237 | 0.720 | 0.739 | 0.691 | |
| KAN-CNQ | 0.233 | 0.230 | 0.247 | 0.729 | 0.731 | 0.690 | |
Survival Analysis
Survival analysis models when events such as disease progression, failure, or death occur, accounting for incomplete follow-up and censoring.
See all 106 papers